Claims for Patent: 6,004,748

Summary for Patent: 6,004,748

Title:	Method of inhibiting transcription utilizing nuclear receptors
Abstract:	This invention provides a method of inhibiting the transcription of a gene, which is activated by AP-1 or an AP-1 component, comprising binding AP-1 or the component with a nuclear receptor so as to prevent the binding of AP-1 to the gene. The nuclear receptor can be the retinoic acid receptor, glucocorticoid receptor, vitamin D3 receptor, thyroid receptor, or estrogen receptor. Also provided is a composition of matter comprising AP-1 or an AP-1 component bound to a nuclear receptor. These methods and compositions can be used to treat arthritis and cancer.
Inventor(s):	Pfahl; Magnus (Solana Beach, CA), Karin; Michael (San Diego, CA)
Assignee:	La Jolla Cancer Research Foundation (La Jolla, CA)
Application Number:	08/757,349
Patent Claims:	1. A method of inhibiting the transcription of a gene, which is activated by AP-1 or an AP-1 component, comprising binding AP-1 or the component with a nuclear receptor so as to prevent the binding of AP-1 to the gene, wherein transcription is inhibited. 2. The method of claim 1, wherein the AP-1 component is a Jun protein. 3. The method of claim 1, wherein the nuclear receptor is a glucocorticoid receptor. 4. The method of claim 1, wherein the nuclear receptor is a vitamin D3 receptor. 5. The method of claim 1, wherein the nuclear receptor is an estrogen receptor. 6. The method of claim 1, wherein the gene is the gene encoding collagenase. 7. The method of claim 1, wherein the receptor is bound to its ligand. 8. The method of claim 1, wherein the nuclear receptor is a retinoic acid receptor. 9. The method of claim 8, wherein the retinoic acid receptor is selected from the group consisting of RAR.epsilon., RAR.alpha. RAR.beta., RAR.tau., and RXR. 10. The method of claim 1, wherein the nuclear receptor is a thyroid receptor. 11. The method of claim 10, wherein the thyroid receptor is selected from the group consisting of erbA-T and TR.alpha.-2. 12. A method of inhibiting the transcription of a gene which is activated by a nuclear receptor which binds AP-1 or an AP-1 component comprising binding the receptor with AP-1 or an AP-1 component so as to prevent the binding of the nuclear receptor to the gene, wherein transcription is inhibited. 13. A composition of matter comprising AP-1 or an AP-1 component bound to a nuclear receptor. 14. The composition of claim 13, wherein the AP-1 component is selected from the group consisting of a Jun and a Fos protein. 15. The composition of claim 13, wherein the nuclear receptor is a glucocorticoid receptor. 16. The composition of claim 13, wherein the nuclear receptor is a vitamin D3 receptor. 17. The composition of claim 13, wherein the nuclear receptor is an estrogen receptor. 18. The composition of claim 13, wherein the nuclear receptor is a retinoic acid receptor. 19. The composition of claim 18 wherein the retinoic acid receptor is selected from the group consisting of RAR.epsilon., RAR.alpha., RAR.beta. and RAR.tau. and RXR. 20. The composition of claim 13, wherein the nuclear receptor is a thyroid receptor. 21. The composition of claim 20, wherein the thyroid receptor is selected from the group consisting of erbA-T and TR.alpha.-2. 22. A method of promoting the transcription of a gene which is activated by AP-1 or an AP-1 component, comprising preventing the binding of AP-1 or an AP-1 component with a nuclear receptor thereby allowing AP-1 to bind the gene, wherein transcription is promoted.

Details for Patent 6,004,748

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2010-10-10